{
  "extraction_metadata": {
    "timestamp": "2025-09-17T12:53:01.477473",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "total_picos": 46
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + Sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "local hepatic therapies",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "transarterial chemoembolization",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "transarterial embolization",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "radiotherapy",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "supportive care",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "systemic chemotherapy",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "radiofrequency ablation",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "microwave ablation",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "other ablations (laser ablation, cryoablation, HIFU, irreversible electroporation)",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "alcohol injection",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "acetic acid injection",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "liver resection",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "liver transplantation",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, health status (measured by EQ-5D VAS), health-related quality of life (global health status, function scales of EORTC QLQ-C30, function scales of EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5863
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response according to RECIST 1.1 and modified RECIST [mRECIST] criteria for liver disease), duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response according to RECIST 1.1 and modified RECIST [mRECIST] criteria for liver disease), duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response according to RECIST 1.1 and modified RECIST [mRECIST] criteria for liver disease), duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response according to RECIST 1.1 and modified RECIST [mRECIST] criteria for liver disease), duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "Patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response according to RECIST 1.1 and modified RECIST [mRECIST] criteria for liver disease), duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "advanced or unresectable hepatocellular carcinoma that has not previously been treated with any other systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response according to RECIST 1.1 and modified RECIST [mRECIST] criteria for liver disease), duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "patients with advanced and/ or unresectable hepatocarcinoma, Child-Pugh EMI, in the absence of grade 0 or grade 3-4",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response according to RECIST 1.1 and modified RECIST [mRECIST] criteria for liver disease), duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 8377
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival, progression-free survival, time to radiological disease progression, time to symptomatic disease progression (measured by FHSI-8 questionnaire), adverse events (including serious adverse events such as diarrhoea and hand-foot skin reaction), discontinuation of treatment due to adverse events, health-related quality of life, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)"
        },
        {
          "Population": "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "overall survival, progression-free survival, time to radiological disease progression, time to symptomatic disease progression (measured by FHSI-8 questionnaire), adverse events (including serious adverse events such as diarrhoea and hand-foot skin reaction), discontinuation of treatment due to adverse events, health-related quality of life, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)"
        },
        {
          "Population": "most patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": "overall survival, progression-free survival, time to radiological disease progression, time to symptomatic disease progression (measured by FHSI-8 questionnaire), adverse events (including serious adverse events such as diarrhoea and hand-foot skin reaction), discontinuation of treatment due to adverse events, health-related quality of life, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5749
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "overall survival, time to symptom progression, time to progression, disease control (including partial response, minor response defined as reduction of tumour size by 25 to 50%, and stable disease for at least 16 weeks), adverse reactions (including serious adverse reactions and grade 3/4 adverse reactions), safety and tolerability in patients with hepatic dysfunction, cost-effectiveness analysis (including total treatment costs and budget impact)"
        },
        {
          "Population": "patients with hepatocellular carcinoma in whom initiation of curative treatment or (continuation) of locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best care regimen available",
          "Outcomes": "overall survival, time to symptom progression, time to progression, disease control (including partial response, minor response defined as reduction of tumour size by 25 to 50%, and stable disease for at least 16 weeks), adverse reactions (including serious adverse reactions and grade 3/4 adverse reactions), safety and tolerability in patients with hepatic dysfunction, cost-effectiveness analysis (including total treatment costs and budget impact)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5588
    },
    "CZ": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "CZ",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "therapeutic value, interchangeability with medicines included in the insured package"
        }
      ],
      "ChunksUsed": 2,
      "ContextTokens": 404
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause, with censoring at cut-off date or last contact), progression-free survival (PFS, defined as time from randomization to disease progression or death), time to progression (defined as time from randomization to disease progression), objective response rate, disease control rate, clinical benefit rate, adverse events (including serious adverse events, grade 3 adverse reactions, treatment-related deaths, and specific events such as hepatotoxicity, hypertension, loss of appetite, weight loss, hepatic encephalopathy, hepatic insufficiency, decreased appetite, arterial thromboembolic events, haemorrhagic events, hypothyroidism, renal events, and hand-foot syndrome), discontinuation of treatment due to adverse events, health-related quality of life (assessed using EQ5D-3L, EORTC QLQ-C30, and EORTC QLQ-HCC18 questionnaires)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7930
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, adverse events (including serious adverse events and adverse reactions leading to discontinuation of treatment), health-related quality of life (including quality of life weights and health state utility values), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY, cost-benefit analysis), resource use estimates, Eastern Cooperative Oncology Group Performance Status (ECOG PS), Child-Pugh scale for liver function, tumour spread assessment (size, number, vascular invasion, extrahepatic spread, TNM system), time in health states (progression-free, progressive illness, death) in partitioned survival model"
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, adverse events (including serious adverse events and adverse reactions leading to discontinuation of treatment), health-related quality of life (including quality of life weights and health state utility values), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY, cost-benefit analysis), resource use estimates, Eastern Cooperative Oncology Group Performance Status (ECOG PS), Child-Pugh scale for liver function, tumour spread assessment (size, number, vascular invasion, extrahepatic spread, TNM system), time in health states (progression-free, progressive illness, death) in partitioned survival model"
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Lenvima (lenvatinib)",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, adverse events (including serious adverse events and adverse reactions leading to discontinuation of treatment), health-related quality of life (including quality of life weights and health state utility values), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY, cost-benefit analysis), resource use estimates, Eastern Cooperative Oncology Group Performance Status (ECOG PS), Child-Pugh scale for liver function, tumour spread assessment (size, number, vascular invasion, extrahepatic spread, TNM system), time in health states (progression-free, progressive illness, death) in partitioned survival model"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6289
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD), disease control rate (DCR), adverse events (including serious adverse events and grade 3 or 4 adverse events), treatment-emergent adverse events (TEAEs), discontinuation, dose reduction, or suspension due to adverse events, number needed to harm (NNH), number needed to treat (NNT), health-related quality of life (measured by EQ-5D and EQ VAS, assessing mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and a visual analogue scale 0-100), quality of life (measured by FACT-G questionnaire, covering physical, family/social, emotional, and functional well-being), hazard ratio (HR), mean difference (MD), relative risk (RR), risk difference (RD)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7298
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), health status (measured by European Quality of Life – 5 Dimensions Visual Analogue Scale, EQ-5D VAS), health-related quality of life (measured by global health status and function scales of EORTC QLQ-C30 and EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work, discontinuation due to adverse events"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), health status (measured by European Quality of Life – 5 Dimensions Visual Analogue Scale, EQ-5D VAS), health-related quality of life (measured by global health status and function scales of EORTC QLQ-C30 and EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work, discontinuation due to adverse events"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + Sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), health status (measured by European Quality of Life – 5 Dimensions Visual Analogue Scale, EQ-5D VAS), health-related quality of life (measured by global health status and function scales of EORTC QLQ-C30 and EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work, discontinuation due to adverse events"
        },
        {
          "Population": "HCC patients with PVT",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), health status (measured by European Quality of Life – 5 Dimensions Visual Analogue Scale, EQ-5D VAS), health-related quality of life (measured by global health status and function scales of EORTC QLQ-C30 and EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work, discontinuation due to adverse events"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), health status (measured by European Quality of Life – 5 Dimensions Visual Analogue Scale, EQ-5D VAS), health-related quality of life (measured by global health status and function scales of EORTC QLQ-C30 and EORTC QLQ-HCC18), symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work, discontinuation due to adverse events"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5944
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), duration of response, time to response, disease control rate (DCR, mRECIST), clinical benefit rate (CBR), adverse events (including serious adverse events, treatment-emergent adverse events, adverse events leading to discontinuation, adverse events occurring in more than 5% of patients), health-related quality of life (HRQoL, measured by EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D questionnaires), time to clinically meaningful deterioration in HRQoL domains (role functioning, pain, diarrhoea from EORTC QLQ-C30; nutrition, body image from EORTC QLQ-HCC18), plasma pharmacokinetics parameters, pharmacokinetic/pharmacodynamic relationship between exposure and efficacy/safety, resource use estimates, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)"
        },
        {
          "Population": "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), duration of response, time to response, disease control rate (DCR, mRECIST), clinical benefit rate (CBR), adverse events (including serious adverse events, treatment-emergent adverse events, adverse events leading to discontinuation, adverse events occurring in more than 5% of patients), health-related quality of life (HRQoL, measured by EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D questionnaires), time to clinically meaningful deterioration in HRQoL domains (role functioning, pain, diarrhoea from EORTC QLQ-C30; nutrition, body image from EORTC QLQ-HCC18), plasma pharmacokinetics parameters, pharmacokinetic/pharmacodynamic relationship between exposure and efficacy/safety, resource use estimates, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)"
        },
        {
          "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), duration of response, time to response, disease control rate (DCR, mRECIST), clinical benefit rate (CBR), adverse events (including serious adverse events, treatment-emergent adverse events, adverse events leading to discontinuation, adverse events occurring in more than 5% of patients), health-related quality of life (HRQoL, measured by EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D questionnaires), time to clinically meaningful deterioration in HRQoL domains (role functioning, pain, diarrhoea from EORTC QLQ-C30; nutrition, body image from EORTC QLQ-HCC18), plasma pharmacokinetics parameters, pharmacokinetic/pharmacodynamic relationship between exposure and efficacy/safety, resource use estimates, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6670
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), quality of life (assessed by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), pharmacokinetic parameters, safety assessments (including vital signs, laboratory haematological and biochemical testing, urinalysis, electrocardiography), adverse events (graded according to the National Cancer Institute), discontinuation due to adverse events, dose reduction due to adverse events, drug withdrawal due to adverse events, grade 3 and 4 adverse reaction rate, treatment-related mortality, dropout rate for toxicity"
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), quality of life (assessed by EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), pharmacokinetic parameters, safety assessments (including vital signs, laboratory haematological and biochemical testing, urinalysis, electrocardiography), adverse events (graded according to the National Cancer Institute), discontinuation due to adverse events, dose reduction due to adverse events, drug withdrawal due to adverse events, grade 3 and 4 adverse reaction rate, treatment-related mortality, dropout rate for toxicity"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5019
    }
  }
}